ID | 61391 |
フルテキストURL | |
著者 |
Harada, Daijiro
Department of Thoracic Oncology, National Hospital Organization Shikoku Cancer Center
Isozaki, Hideko
Department of Clinical Pharmaceutics, Okayama University Hospital
Kozuki, Toshiyuki
Department of Thoracic Oncology, National Hospital Organization Shikoku Cancer Center
Yokoyama, Toshihide
Department of Respiratory Medicine, Kurashiki Central Hospital
Yoshioka, Hiroshige
Department of Respiratory Medicine, Kurashiki Central Hospital
Bessho, Akihiro
Department of Respiratory Medicine, Japanese Red Cross Okayama Hospital
Hosokawa, Shinobu
Department of Respiratory Medicine, Japanese Red Cross Okayama Hospital
Takata, Ichiro
Department of Internal Medicine, Fukuyama City Hospital
Takigawa, Nagio
Kaken ID
researchmap
Hotta, Katsuyuki
Department of Respiratory Medicine, Okayama University Hospital
Kaken ID
publons
researchmap
Kiura, Katsuyuki
Department of Respiratory Medicine, Okayama University Hospital
ORCID
Kaken ID
publons
researchmap
Okayama Lung Cancer Study Group
|
抄録 | Background
The efficacy of crizotinib treatment for recurring EML4‐ALK‐positive non‐small cell lung cancer (NSCLC) previously treated with alectinib is unclear. Based on our preclinical findings regarding hepatocyte growth factor/mesenchymal epithelial transition (MET) pathway activation as a potential mechanism of acquired resistance to alectinib, we conducted a phase II trial of the anaplastic lymphoma kinase/MET inhibitor, crizotinib, in patients with alectinib‐refractory, EML4‐ALK‐positive NSCLC.
Methods
Patients with ALK‐rearranged tumors treated with alectinib immediately before enrolling in the trial received crizotinib monotherapy. The objective response rate was the primary outcome of interest.
Results
Nine (100%) patients achieved a partial response with alectinib therapy with a median treatment duration of 6.7 months. Crizotinib was administered with a median treatment interval of 50 (range, 20–433) days. The overall response rate was 33.3% (90% confidence interval [CI]: 9.8–65.5 and 95% CI: 7.5–70.1), which did not reach the predefined criteria of 50%. Two (22%) patients who achieved a partial response had brain metastases at baseline. Progression‐free survival (median, 2.2 months) was not affected by the duration of treatment with alectinib. The median survival time was 24.1 months. The most common adverse events were an increased aspartate transaminase/alanine transaminase (AST/ALT) ratio (44%) and appetite loss (33%); one patient developed transient grade 4 AST/ALT elevation, resulting in treatment discontinuation. Other adverse events were consistent with those previously reported; no treatment‐related deaths occurred.
Conclusions
Although the desired response rate was not achieved, crizotinib monotherapy following treatment with alectinib showed efficacy alongside previously described adverse events.
|
キーワード | Alectinib
anaplastic lymphoma kinase
crizotinib
drug therapy
non-small cell lung carcinoma
|
発行日 | 2021-01-20
|
出版物タイトル |
Thoracic Cancer
|
巻 | 12巻
|
号 | 5号
|
出版者 | Wiley
|
開始ページ | 643
|
終了ページ | 649
|
ISSN | 1759-7706
|
資料タイプ |
学術雑誌論文
|
言語 |
英語
|
OAI-PMH Set |
岡山大学
|
著作権者 | © 2021 The Authors.
|
論文のバージョン | publisher
|
PubMed ID | |
DOI | |
Web of Science KeyUT | |
関連URL | isVersionOf https://doi.org/10.1111/1759-7714.13825
|
ライセンス | https://creativecommons.org/licenses/by-nc-nd/4.0/
|